Post-Essential Thrombocythemia MF (Post-ET-MF)
1 clinical trials · Condition
◉ Watch Post-Essential Thrombocythemia MF (Post-ET-MF)
| Record | Firm | Date |
|---|---|---|
| KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment (NCT03662126) | Kartos Therapeutics, Inc. | 2019-01-15 |
Track Post-Essential Thrombocythemia MF (Post-ET-MF) automatically
Every clearance here is in the API, with alerts when new ones post.